The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...